Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer
- 20 January 2009
- journal article
- review article
- Published by Springer Nature in Targeted Oncology
- Vol. 4 (1) , 37-44
- https://doi.org/10.1007/s11523-009-0104-2
Abstract
Elderly and poor performance status advanced non-small cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib and gefitinib, are active agents in the treatment of advanced NSCLC. Several phase II trials have been conducted utilizing EGFR TKIs in elderly or poor performance status patients with advanced NSCLC. This review will summarize the results of erlotinib or gefitinib in these subsets of patients with advanced NSCLC.Keywords
This publication has 65 references indexed in Scilit:
- Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2Journal of Thoracic Oncology, 2008
- Randomized Phase II Trial of Paclitaxel Plus Carboplatin or Gemcitabine Plus Cisplatin in Eastern Cooperative Oncology Group Performance Status 2 Non–Small-Cell Lung Cancer Patients: ECOG 1599Journal of Clinical Oncology, 2007
- Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: Retrospective analysis of 575 Korean patientsLung Cancer, 2006
- Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2006
- Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: Results from a prospective feasibility studyLung Cancer, 2005
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004